Uncategorized drug pipelines

Astellas

FK949E Quetiapine

Depression, bipolar

Phase II/III


AstraZeneca

AZD8108

Suicidal ideation

Phase I


Dainippon Sumitomo Pharma

DSP-1200

Depression

Phase I


Dainippon Sumitomo Pharma

SEP-363856

Schizophrenia

Phase I


Dainippon Sumitomo Pharma

Lurasidone Hydrochloride

Schizophrenia

Phase III


Dainippon Sumitomo Pharma

Blonanserin

Schizophrenia

Phase III


Neuren Pharmaceuticals

NNZ-2591

"Other" neurological conditions

Preclinical/Phase I


Roche

RG7203

Schizophrenia

Phosphodiesterase-10A (PDE-10A) inhibitor

Phase I


Shire

Intuniv

ADHD

Approval


Shire

SHP-465

ADHD

Approval


Shire

Vyvanse

ADHD

Phase II/III


Takeda

TAK-041

Schizophrenia

GPR139 agonist (oral)

Phase I


Teva

deutetrabenazine

Tourette syndrome

Phase I


Takeda

Lu AA24530

Major depressive disorder, generalized anxiety disorder

Discontinued Phase I


Takeda

TAK-137

psychiatric disorders

Discontinued Phase I


Takeda

TAK-915

schizophrenia

PDE 2A inhibitor

Phase I


Takeda

TAK-653

psychiatric disorders

AMPA receptor potentiator

Phase I


Takeda

TAK-58

schizophrenia

5- HT3 receptor antagonist

Phase I


Takeda

TAK-63

schizophrenia

PDE10A inhibitor

Phase II


Takeda

vortioxetine

major depressive disorder & ADHD

multimodal anti-depressant

Phase II & III


Roche

RG7314

autism

small molecule antagonist of V1A vasopressin receptor

Phase II


Roche

RG7203

schizophrenia

inhibitor of phosphodiesterase 10A

Phase I


Pfizer

PF-06266047

Schizophrenia

Phase I


Pfizer

PF-04958242

Schizophrenia

Phase I


Otsuka

nalmefene

alcohol dependence

Opioid receptor antagonist

Phase III


Otsuka

deuterium-modified dextromethorphan, quinidine

major depressive disorder, schizophrenia

NMDA receptor antagonist/Serotonin and Norepinephrine reuptake inhibitor/Sigma-1 receptor agonist/Neuronal nicotinic receptor antagonist

Phase II


Otsuka

brexpiprazole

major depressive disorder, schizophrenia, PTSD

Dopamine partial agonist

Phase III


Otsuka

aripiprazole

autism, bipolar

Dopamine partial agonist

Phase III & Approval


Merck

verubecestat

Alzheimer's disease

inhibitor of beta-site amyloid precursor protein cleaving enzyme 1 (BACE)

Phase III


Johnson & Johnson

esketamine

Depression (treatment resistant)

Phase III


Johnson & Johnson

paliperidone palmitate

Schizophrenia

Approved (US)


Roche

RG7906

psychiatric disorders

Phase I


Eli lilly

Pomaglumetad methionil

Schizophrenia

Agonist of the metabotropic glutamate 2/3 receptors

Phase I


Shire

Guanfacine

ADHD

Phase III


Sunovion

DSP-1200

Depression (treatment resistant)

Phase I


Sunovion

DSP-3740

schizophrenia

Phase I


Sunovion

SEP-856

Schizophrenia

Phase I


Sunovion

Dasotraline

ADHD (pediatric and adult), binge eating disorder

Phase III


Sunovion

Latuda

schizophrenia, bipolar (pediatric)

Phase III


Sumitomo Dainippon Pharma

SEP-225289 (dasotraline)

Attention-deficit hyperactivity disorder

Phase III


Sunovion

Latuda

Bipolar disorder

Phase III


Johnson & Johnson

paliperidone palmitate IM long acting injectable

Schizophrenia

Phase III


Otsuka

aripirazole, sertraline

Major depressive disorder

Dopamine partial agonist/ Selective serotonin reuptake inhibitor

Phase III


Otsuka

brexpiprazole

Posttraumatic stress disorder

Dopamine partial agonist

Phase III